A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2016
At a glance
- Drugs LCL 161 (Primary) ; Paclitaxel
- Indications Breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.